Key Takeaways
- IGF-1 LR3 is an engineered analog of insulin-like growth factor 1, not a synonym for native IGF-1.
- The LR3 design changes how the analog interacts with IGF-binding proteins, making binding-protein context central to interpreting experiments.
- Published studies measure IGF1R-linked pathways such as PI3K/Akt and ERK, but results vary by cell type, tissue, species, and experimental design.
- The evidence set includes biochemical, cell, tissue, and animal studies; it does not establish human efficacy or safety.
- A recent 5XFAD mouse study reported amyloid-plaque remodeling without preserved cognitive function, a useful example of biomarker-function separation.
- The WebberScience 1mg label identifies vial quantity only. It is not a dose, route, research amount, administration instruction, or protocol.
IGF-1 LR3, also written long R3 IGF-I, is a modified IGF-1 analog used to investigate growth-factor signaling under controlled laboratory conditions. Its structural changes distinguish it from native IGF-1 and alter the importance of IGF-binding proteins in experimental systems. Researchers have used long R3 IGF-I in cell proliferation, differentiation, cardiac, ovarian, mammary, intestinal, cancer-cell, and brain-model studies. Those publications reveal biologically active signaling, but they do not support a universal outcome or an established human use.
Research boundary: This article is scientific education, not medical advice. WebberScience materials are for research and laboratory use only, not for human or veterinary use. No dosing, route, administration, treatment, performance, or self-experimentation guidance is provided.
What Is IGF-1 LR3?
Native IGF-1 and the engineered analog are different materials
Insulin-like growth factor 1, or IGF-1, is an endogenous signaling protein encoded by the human IGF1 gene. It participates in the growth hormone–IGF axis and can act through endocrine, paracrine, and autocrine contexts. IGF-1 LR3 is an engineered analog rather than the native sequence.
Structural work describes long-[Arg3]IGF-I as an IGF-I analog with an arginine substitution at position 3 and an N-terminal extension. A solution-structure study indexed as PMID 10744677 examined its folding and backbone dynamics, while earlier recombinant work indexed as PMID 1311930 characterized potent position-3 IGF-I analogs. These records support the structural distinction. They do not justify treating every catalog material as analytically identical without product-specific characterization.
Why the “long R3” name matters
The name is useful because it prevents a common evidence error: transferring a result from native IGF-1 to LR3, or from LR3 to native IGF-1, without checking which material was actually tested. Even when both engage the IGF system, differences in sequence, binding-protein interaction, exposure, and assay design can change the measured response.
IGF-Binding Proteins: The Central Experimental Variable
What are IGFBPs?
IGF-binding proteins (IGFBPs) are extracellular proteins that bind IGFs and regulate their availability. They are not passive labels. Their abundance, proteolysis, cellular source, and local environment can change receptor access and downstream signaling.
A 2007 bovine preantral-follicle study (PMID 17636166) explicitly described long R3 IGF-I as an analog with low affinity for IGFBPs. Both native IGF-I and LR3 increased follicle diameter and estradiol production in the six-day culture system. However, follicles exposed to LR3 or the highest native-IGF-I concentration also showed smaller oocyte-to-follicle ratios and more oocyte degeneration than selected comparison conditions. The authors concluded that IGFBP regulation was necessary for coordinated follicular development in that model.
Reduced affinity does not mean “no binding-protein effect”
The evidence is more nuanced than a simple bypass claim. In PMID 11735239, IGFBP-3 inhibited receptor phosphorylation induced by native IGF-I and several analogs, including long R3 IGF-I, under the tested conditions. In L6 myogenic cells (PMID 15254966), recombinant IGFBP-3 suppressed proliferation stimulated by both native IGF-I and LR3, while its effect on differentiation differed between the two materials.
Together, these studies show why “reduced IGFBP affinity” should not be translated into “IGFBPs are irrelevant.” The observed biology depends on the binding protein, assay, cell model, endpoint, and analog.
How Does IGF-1 LR3 Signal in Experimental Models?
IGF1R, PI3K/Akt, and ERK
IGF1R is the type 1 IGF receptor, a receptor tyrosine kinase. Receptor activation can engage intracellular pathways that include phosphoinositide 3-kinase (PI3K), Akt, and extracellular signal-regulated kinase (ERK). These pathways regulate many processes, so pathway activation is not itself evidence of one desired outcome.
A fetal sheep cardiomyocyte study (PMID 12947030) used long R3 IGF-I in vivo and in culture. In cultured cells, LR3 increased bromodeoxyuridine uptake, a DNA-synthesis measure. Blocking either ERK or PI3K abolished the measured proliferation response. Importantly, the study did not find LR3-induced cardiomyocyte hypertrophy in vivo or in vitro. That negative result keeps “proliferation” separate from “cell enlargement.”
In mouse mammary tissue (PMID 18577570), LR3 increased mammary phospho-Akt and SOCS3 expression and had only a modest effect on the study’s lactation-capacity measure. Again, a signaling change and a functional endpoint were not equivalent.
Cell proliferation can be a research endpoint and a safety question
Human prostate cancer cell-line work (PMID 12843187) reported increased telomerase activity after native IGF-I or long R3 IGF-I exposure. The native-IGF-I effect was abolished by an Akt-pathway inhibitor, while MAPK blockade did not remove it. This is a cancer-cell experiment, not a claim about healthy tissue or people. It does demonstrate why mitogenic and proliferative pathways require cautious interpretation rather than promotional wording.
What Has IGF-1 LR3 Research Actually Examined?
| Model | Material and endpoint | Reported finding | Interpretive limit |
|---|---|---|---|
| Bovine follicles in vitro | Native IGF-I vs LR3; growth, estradiol, morphology | Growth-related measures increased; selected conditions also showed degeneration | Culture model; outcomes were not uniformly favorable |
| Fetal sheep cardiomyocytes | LR3; DNA synthesis, ERK/PI3K, cell size | Proliferation signal required ERK and PI3K; no hypertrophy found | Developmental sheep model, not adult human muscle |
| Mouse mammary tissue | LR3; phospho-Akt, gene expression, lactation capacity | Signaling changed; functional effect was modest | Species- and tissue-specific physiology |
| Human cancer cell lines | IGF-I/LR3; telomerase-related measurements | Telomerase activity increased in cultured cells | Cancer cells outside an intact person |
| 5XFAD mice | Intranasal LR3; amyloid and behavior | Plaque characteristics changed; cognition was not preserved | Transgenic mouse model; biomarker did not equal function |
A recent brain-model study provides a useful negative result
The 2025 study indexed as PMID 39610283 evaluated long R3 IGF-1 in male 5XFAD mice, a transgenic amyloid model. The title and abstract report remodeling of cortical amyloid plaques but failure to preserve cognitive function. This is valuable evidence because it resists a common shortcut: assuming that a changed tissue marker necessarily predicts a meaningful behavioral result.
Researchers should retain the exact model boundary. A 5XFAD mouse result does not establish an Alzheimer’s intervention, human cognitive effect, or general neuroprotective property.
IGF-1 LR3 Compared With Related Research Materials
| Material | Primary research context | Binding-protein context | Key boundary |
|---|---|---|---|
| Native IGF-1 | Endogenous IGF biology and IGF1R signaling | Strongly regulated by IGFBPs | Not structurally identical to LR3 |
| IGF-1 LR3 | Engineered analog for receptor, cell, and tissue studies | Lower IGFBP affinity is reported, but IGFBP effects can remain measurable | No established human efficacy or safety in this evidence set |
| HGH Fragment 176-191 | Growth-hormone-fragment research | Different material and evidence base | Not an IGF-1 analog |
| AOD9604 | Modified growth-hormone-fragment research | Different target context | Results cannot be transferred to LR3 |
For broader topic mapping, see WebberScience’s HGH peptides research guide and tissue-research overview. Those hub pages compare research categories; this article answers the narrower IGF-1 LR3 structure, binding-protein, signaling, and evidence-quality intent.
What the Evidence Does Not Establish
- No universal half-life number: the reviewed PubMed abstracts did not establish one transferable “20-hour” estimate across models and materials.
- No proven human outcome: cell, tissue, and animal results do not demonstrate human muscle growth, recovery, metabolic benefit, cognition, or another clinical effect.
- No established human safety: receptor selectivity or pathway activation is not a clinical safety assessment.
- No model equivalence: follicles, cardiomyocytes, mammary tissue, cancer cells, and transgenic mice answer different questions.
- No product-study equivalence: a catalog label does not prove analytical identity with every recombinant analog used in publications.
- No protocol: experimental concentrations, exposures, and procedures in papers are methods, not instructions.
A 2026 narrative review (PMID 42395176) placed IGF-1 LR3 among unregulated GH–IGF-axis materials and emphasized uncertainty around composition, exposure, and unproven performance claims. That review is context rather than a primary LR3 experiment, but its caution aligns with the gaps visible in the primary evidence.
Key Terms and Definitions
- IGF-1
- Insulin-like growth factor 1, an endogenous signaling protein involved in the GH–IGF axis.
- IGF-1 LR3
- An engineered long R3 analog of IGF-1 used in laboratory studies.
- IGFBP
- An insulin-like growth factor-binding protein that regulates extracellular IGF availability.
- IGF1R
- The type 1 IGF receptor, a receptor tyrosine kinase.
- PI3K/Akt
- A signaling pathway measured in many IGF-system experiments.
- ERK
- Extracellular signal-regulated kinase, part of a MAP-kinase pathway.
- Preclinical evidence
- Biochemical, cell, tissue, or animal research conducted before or outside confirmatory human clinical studies.
Frequently Asked Questions About IGF-1 LR3
What is IGF-1 LR3?
IGF-1 LR3, also called long R3 IGF-I, is an engineered analog of insulin-like growth factor 1 used in laboratory research. Published experiments use it to study IGF receptor signaling, binding-protein regulation, cell proliferation, differentiation, and tissue-specific responses.
What does LR3 mean in IGF-1 LR3?
The name identifies a long analog with an arginine substitution at position 3. Structural literature also describes an N-terminal extension. Those changes distinguish the research analog from native IGF-1.
Is IGF-1 LR3 the same as native IGF-1?
No. The two materials share IGF biology, but LR3 is structurally modified and is commonly used where researchers want less constraint from IGF-binding proteins. Results from one material should not automatically be assigned to the other.
Why are IGF-binding proteins important?
IGF-binding proteins regulate IGF availability in extracellular environments. Studies show that IGFBP-3 can alter receptor phosphorylation, proliferation, and differentiation responses, so the binding-protein context can change how an experiment behaves.
What receptor does IGF-1 LR3 activate?
Long R3 IGF-I is used as an IGF1R agonist in experimental systems. Downstream measurements in cited studies include receptor phosphorylation, PI3K/Akt signaling, ERK signaling, DNA synthesis, and differentiation markers.
Does IGF-1 LR3 have a proven 20-hour half-life?
The reviewed PubMed abstracts did not provide a universal 20-hour pharmacokinetic estimate that could be applied across species, tissues, formulations, and study designs. A responsible research summary should report the exact pharmacokinetic method and model rather than repeat an unsourced catalog number.
What cell types have been studied with long R3 IGF-I?
The cited literature includes myogenic cells, fetal sheep cardiomyocytes, bovine ovarian follicles, mouse mammary tissue, and human prostate cancer cell lines. Each model answers a different biological question.
What did muscle-related studies find?
Myogenic-cell studies found that IGFBP-3 changed proliferation and differentiation responses to native IGF-I and long R3 IGF-I. These controlled cell findings do not establish muscle growth, recovery, or performance outcomes in humans.
Has IGF-1 LR3 been studied in brain research?
Yes. A recent 5XFAD mouse study reported changes in cortical amyloid-plaque characteristics but no preservation of cognitive function. That mixed result illustrates why a biomarker change should not be treated as a functional benefit.
Has IGF-1 LR3 been proven effective in people?
The evidence set reviewed here is dominated by biochemical, cell, tissue, and animal research. It does not establish controlled human efficacy or safety for IGF-1 LR3 as a research material.
What does 1mg mean on the WebberScience product page?
It is the labeled quantity of research material in the vial listing. It is not a dose, research amount, route, administration instruction, or experimental protocol.
Where can Canadian researchers find IGF-1 LR3 research material?
WebberScience lists IGF-1 LR3 1mg for qualified laboratory research in Canada. Researchers should review the live product documentation and independently define analytical, storage, and experimental controls.
Sources
- Laajoki LG, et al. “Solution structure and backbone dynamics of long-[Arg3]insulin-like growth factor-I.” Journal of Biological Chemistry. 2000. PMID 10744677.
- Thomas FH, et al. “Effects of IGF-I bioavailability on bovine preantral follicular development in vitro.” Reproduction. 2007. PMID 17636166.
- Devi GR, et al. “Effect of IGFBP-3 on IGF- and IGF-analogue-induced IGFIR signalling.” Growth Hormone & IGF Research. 2001. PMID 11735239.
- Xi G, et al. “Effect of recombinant porcine IGFBP-3 on IGF-I and long-R3-IGF-I-stimulated proliferation and differentiation of L6 myogenic cells.” Journal of Cellular Physiology. 2004. PMID 15254966.
- Sundgren NC, et al. “ERK and PI3K mediate IGF-1 induced proliferation of fetal sheep cardiomyocytes.” American Journal of Physiology. 2003. PMID 12947030.
- Hadsell DL, et al. Long-R3-IGF-I, mammary signaling, and prolonged lactation in mice. Journal of Endocrinology. 2008. PMID 18577570.
- Wetterau LA, et al. “Insulin-like growth factor I stimulates telomerase activity in prostate cancer cells.” JCEM. 2003. PMID 12843187.
- Engel MG, et al. Long R3 IGF-1 in male 5XFAD mice: plaque remodeling without preserved cognition. Journal of Alzheimer’s Disease. 2025. PMID 39610283.
- Dominikowski A, et al. GH–IGF1-axis performance-enhancing peptides: evidence and self-administration gap. Frontiers in Endocrinology. 2026. PMID 42395176.
IGF-1 LR3 for Laboratory Research in Canada
Qualified researchers can review WebberScience IGF-1 LR3 1mg laboratory material and the live Tissue & Recovery Research catalog. The 1mg label identifies the listed vial quantity only; it is not a suggested amount, dose, route, administration instruction, or protocol.
For broader same-brand educational context, browse the WebberScience peptide research library.
Research disclaimer: For research and laboratory use only. Not intended for human or veterinary use. This article does not constitute medical advice. WebberScience does not provide dosing, route, administration, treatment, efficacy, performance, or safety guidance.